Clearmind Medicine (CMND) announced the publication of a U.S. patent application expanding coverage of its non-hallucinogenic proprietary compound, 5-methoxy-2-aminoindane, for the treatment of cocaine addiction. MEAI is a novel, non-hallucinogenic neuroplastogen designed to modulate serotonin and dopamine pathways, potentially reducing cravings and supporting long-term recovery. This approach could offer a safer, scalable alternative to existing behavioral interventions.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- Psychedelic: Compass Pathways, NeuroKaire enter R&D collaboration
- Clearmind Medicine completes first cohort treatment in Phase I/IIa AUD trial
- Clearmind appoints Mary-Elizabeth Gifford as chief of global impact
- Psychedelic: Clearmind enrolls last patient in first cohort of CMND-100 trial
- Clearmind Medicine enrolls last patient for first cohort of CMND-100 trial